Clinical study of outcome in the management of BPH with obstructive nephropathy

Dr. Vikram and Dr. Chandra Mouli

DOI: https://doi.org/10.33545/surgery.2021.v5.i1e.621

Abstract

Background: Benign Prostate Hyperplasia (BPH) is a common disease in adult men and its incidence is age related. While the underlying mechanism for developing renal failure associated with benign prostatic hyperplasia is likely multifactorial and co-morbid factors in elderly men may contribute to renal impairment. We aimed to determine the association of benign prostatic obstruction with nephropathy.

Materials and Methods: A Prospective study was conducted at JSS Hospital, Karnataka, between June 2010 to June 2012. A total 30 patients were included after informed consent. Blood samples were collected from all the subjects. IPSS, QoL Score, Residual urine, Serum Creatinine, Prostatic volume and Hemodialysis was done.

Results: The present study evaluates the IPSS and QoL Score. Residual urine. Serum Creatinine. Prostatic volume and Hemodialysis in patients with BPH showed a positive relation with nephropathy. Along with that we analyzed all the parameters pre and post OP IPSS (24.75 ± 1.88, 14.27±3.66), QoL Score (4.65 ±0.66, 1.93±0.75), Residual urine442.48±225.65, 44.89± 47.50), Serum Creatinine (3.04± 2.13 1.28±0.49), and Hemodialysis (3(10%), 2 (6%).

Conclusion: This study concludes Strong inter-relation between the two such that BPH can cause renal failure while renal failure can influence the management of BPH and its outcome.

Keywords: BPH, Serum Creatinine, Obstructive Nephropathy.

Introduction

Benign Prostate Hyperplasia (BPH) is a common disease in adult men and its incidence is age related. Prevalence of BPH is approximately 25% in men aged 40 to 49 years, 50% in men aged 50 to 59 years and 80% in men aged 70 to 79 years [1]. If we have to go by the natural history of the disease progression of BPH and its complications 13.6% of patients who presented to undergo TURP were in renal failure [2]. As we understand that these patients with BPH whether symptomatic or asymptomatic, if left untreated may present with renal failure which could be chronic or acute. Despite the many possible causes of renal failure in elderly patients, the common causes were BPH (38%), neurogenic bladder (19%), obstructive pyleonephritis (15%) [3].

TURP remains the gold standard surgical procedure for treatment of these cases. However, patients in renal failure have an increased risk for complications after TURP compared with patients with normal renal function, so we wanted to study the treatment outcome and complications associated with its management [4]. Attending to high prevalence of BPH in older men with CKD it is invaluable to take into consideration the relationship between these two clinical entities. However, despite the high prevalence of renal failure and BPH in elderly men, there is limited knowledge on the association between these two conditions, there is very little information in the literature regarding the role of only BPH as a causative factor in causing renal failure and its treatment outcome [5]. Based on this background the present study was evaluates the clinical study of outcome in the management of BPH with obstructive nephropathy.

Materials and Methods

A Prospective Study of 30 Consecutive Cases with Obstructive Nephropathy Secondary to BPH Study was conducted at JSS Hospital between June 2010 to June 2012. A total 630 subjects screened at our institute during the study period, out of which patients who had associated renal failure (143 patients) on the basis of serum creatinine value were selected.
Among the patients who had BPH with renal failure cases which satisfied the inclusion criteria 30 patients were selected and rest of the cases with other medical conditions such as diabetes, hypertension, prostatic malignancy, causes of obstructive uropathy other than BPH were excluded. All the subjects were recruited in the study after obtaining their informed consent after obtaining of ethical clearance from the institute. From the all subjects, after overnight fasting (12hrs), 3 ml of venous blood was collected transferred into plain tube. The collected samples were separated by centrifugation at 3000 rpm for 3 min and stored until biochemical analysis was done. International Prostate Symptom Score (IPSS), QoL = Quality of life, Residual urine, Prostatic volume, Hemodialysis and Serum Creatinine were measured by modified jiffy’s method laboratory standard methods.

**Statistical analysis**
The Descriptive procedure displays univariate summary statistics for several variables in a single table and calculates standardized values. Categorical variables were tested using Chi-square test. Comparisons between two groups for continuous variables were assessed using Paired samples t test. The Bivariate Correlations procedures computes Pearson’s correlations coefficient. Correlations measure how variables or the Rank orders are related. Multinomial Logistic Regression is useful for situations in which you want to be able to classify subjects based on values of a set of predictor variables. Statistical analysis was performed using Microsoft Excel spread sheets, PSS software for windows version 16. A P < 0.05 was considered statistically significant.

**Results**
Table – 1In the study population comparison of various variables which could influence the outcome were compared between the group which improved and the group which did not improve by the method of comparison of mean and to know its statistical significance by calculating the p value. Patients who improved after TURP surgery were younger with a mean age of around 65 years than patients who did not improve whose mean age, IPSS, QoL score, Residual urine, Serum creatinine and prostatic volume was around 72 years which was found to be statistically significant (p value=0.0001).

**Table 1:** Showed the demographic characteristics between clinical factors Vs Outcome

| VARIABLES          | Improved N=22 | Not improved N=7 | P value |
|--------------------|---------------|------------------|---------|
| Mean               | SD            | Mean             | SD      |
| Age                | 65.4783       | 6.98615          | 72.4286 | 3.73529 | 0.018 |
| Duration of symptoms | 88.5652      | 119.59539        | 152.1429| 97.37630| 0.213 |
| IPSS               | 24.4783       | 1.87979          | 26.1429 | 1.67816 | 0.045 |
| QoL                | 4.5652        | 5.8977           | 5.0000  | 81.560  | 0.130 |
| Residual Urine     | 463.5652      | 236.32428        | 360.000 | 156.92355 | 0.288 |
| Baseline Sr.Creatinine | 2.4565     | .9202            | 5.3857  | 3.36222 | 0.001 |
| USG Prostate       | 45.5652       | 16.67558         | 44.4286 | 16.52127 | 0.875 |

**Table 2:** Symptomatic improvement, improvement in renal functions and ability to void spontaneously with minimal residual urine the above-mentioned variables were compared in the pre-op and post-op follow up. There was very significant improvement in symptom and quality of life, renal function and voiding pattern which was all found to be statistically very significant (p value=0.000). Dialysis was required in 3(10%) patients in the pre-operative period and 2(6%) patients continued to require Hemodialysis in the post-operative period.

**Comparison of pre-op vs post-op variables**

| Paired Variables | Pre-op N=29 | Post-op N=29 | P value |
|------------------|-------------|--------------|---------|
| Mean             | SD          | Mean         | SD      |
| IPSS             | 24.7586     | 1.88329      | 14.2759 | 3.66340 | 0.000 |
| QOL              | 4.6552      | 0.66953      | 1.9310  | 0.75266 | 0.000 |
| Serum creatinine | 3.84        | 2.13         | 1.28    | .49     | 0.000 |
| Residual urine   | 442.8828    | 225.65       | 44.8966 | 47.50515 | 0.000 |
| Hemodialysis     | 3(10%)      | 2(6%)        |         |         |       |
Table 3: The patients who had complications were analysed by comparing each complication with other variables such as basal renal function, duration of presenting symptoms and residual urine between the groups who had that particular complication with other group who did not have that particular complication by the method of comparison of means.

| VARIABLES                  | Refractory Renal failure |
|----------------------------|--------------------------|
|                            | Yes | No |
|                            | N=3 | N=27 |
| Basal serum creatinine (mg/dl) | 6.35 | 2.64 |
| Duration of symptoms (days) | 130 | 88.5 |
| Residual urine (cc)         | 328.3 | 463 |

Table 4: The association of hypotonia on Urodynamic study with increased complication rate was found to be statistically significant even on multinomial logistic regression analysis.

| Variable                  | Adjusted Odds Ratio | 95% C.I. | P-Value |
|---------------------------|---------------------|----------|---------|
| Age (II <70 or >70 years) | 13.365 | 0.5261 | 339.5151 | 0.1162 |
| Creatinine (if <3 or >3)  | 11.7409 | 0.4845 | 284.5318 | 0.1299 |
| Trabeculations (Grade II/III) | 1.1202 | 0.0439 | 28.5846 | 0.9453 |
| UDE (Hypotonia/normal)    | 27.17 | 1.026 | 769.23 | 0.0491 |

Fig 1: Shows the IPSS Score between obstructive score as well as irritative score, mean irritative score having more than mean obstructive score.

Fig 2: Showed the residual urine data distribution

Fig 3: Shows the comparison of different concentrations of serum creatinine

Discussion
Benign Prostate Hyperplasia (BPH) is a common disease in ageing men with a prevalence of 50% above 50 years and increasing up to 80% in men above 80 years. In our institute it was observed that many patients who presented with obstructive Lower Urinary Tract Symptoms secondary to BPH had associated renal failure. While the underlying mechanism for developing renal failure associated with BPH is multifactorial and co-morbid factors such as diabetes, hypertension, etc in elderly men may contribute to renal impairment [6]. In our study the mean incidence of BPH with renal failure was 11.2%. This was comparable with the other studies. The AHCPR BPH Guidelines report a mean of 13.6% of renal failure [7, 8]. In another study there was a reported incidence of 11% in patients with renal failure secondary to BPH [9]. Previous study’s reported that More recently a cross-sectional survey in Spain of 2,000 randomly sampled men who were 50 years or older showed a 2.4% prevalence of self-reported renal failure related to a prostate condition (9% reported renal failure from any cause) [10]. Another study 21 showed that men presenting for
prostate surgery had a 7.7% prevalence of renal failure compared to a 3.7% prevalence in age-matched men presenting for no prostate surgery. [11]. All the patients had an IPSS suggestive of severe lower urinary tract symptoms with bothersome quality of life score being unhappy and it was also observed that major contribution in their IPSS were from obstructive symptoms as compared to irritative voiding symptoms. Most of the patients have characteristic symptoms such as nocturia, urgency, weak urinary stream, a sense of incomplete bladder emptying, straining during micturition, increased micturition frequency and dribbling during or after urination. [12]. Chronic urinary retention as consequence of BPH has been defined as a palpable bladder that corresponds to a high PVR34 and most of the patients with chronic urinary retention have an indolent and progressive disease, with worsening of urinary symptoms and the majority of these patients just seek for medical care in bad health conditions with sharp renal insufficiency. [13]. In our study most of the patients had severe symptoms with poor quality of life. In spite of having such severe symptom score the delay in seeking medical attention could be attributed to lack of health awareness as most of our patients were from rural setup and also due to the fear of surgery. Many of these patients were silent sufferers and postponed their medical visits till their symptoms became very severe or were precipitated by acute attacks of urinary retention. [14]. In our study serum Creatinine (SC) and Creatinine clearance (Cr. Cl) were taken as criteria for defining renal insufficiency. Serum Creatinine of 1.4mg/dl & Cr. Cl of60nl/min/1.73m2 were taken as the cut-off, a value above which were included in the study. We further arbitrarily categorized the patients with high serum creatinine under 3 groups; patients with serum creatinine levels of 1.5-3.0; 3.1-6.0 and 6.1-12 to quantify the severity of the renal insufficiency. [15]. In our study most of the patients 20(67%) had their SC between 1.5-3.0 mg/dl, 6(26.6%) patients had serum creatinine between 3-6mg/dl and 2(6.4%) patients had serum creatinine above 6mg/dl.

Analysis of certain important clinical and biochemical variables such as IPSS, QoL score, basal renal functions, voiding pattern (as reflected by residual urine), persistence of hydroureretonephrosis, need for dialysis were compared in the pre and post-operative period to determine the role of surgery-TURP in influencing these factors. It was found that there was a statistically significant (p value=0.000) [10]. However only the association of hypotonic on Urodynamic study with increased complication rate was found to be statistically significant even on multivariate analysis. The association of parameters other than hypotonic on Urodynamic study, which were found to be significant on univariate analysis were not found to be statistically significant in increasing the rate of complication on multivariate analysis suggesting bladder hypotonia as an independent risk factor in predicting the final outcome in patients with renal failure.

Conclusion
Increasing incidence of BPH with Renal failure, the role of BPH in causing renal failure has been well established which are also strongly influenced by severity of obstructive symptoms and degree of bladder hypotonia.

Reference
1. Coresh J, Astor Bc, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
2. Haroun Mk, Bernard Gj, Hoffman Sc et al. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-2941.
3. Fox Cs, Larson Mg, Leip Ep. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850.
4. Chen J, Munter P, Hamm Li. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 200;140:167-174.
5. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In Campbell-Walsh Urology, 9th edition. Edited by Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Philadelphia: Saunders-Elsevier 2007, 2727-2765.
6. Yamasaki T, Naganuma T, Iguchi T, Kuroki Y, Kuwabara N, Takemoto Y et al. Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrology 2011;16:335-339.
7. Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauuchi A, Yamaniushi T et al. Japanese Urological Association: Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 2011;18:741-756.
8. Rocco B, Albo G, Ferreira RC, Spinelli M, Cozzi G, Dell’orto P et al. Recent advances in the surgical treatment of benign prostatic hyperplasia. Ther Adv Urol 2011;3:263-272.
9. Jung Y, Park J, Kim HL, Yonh DH, Kang J, Lim S et al. Vanillic acid attenuates testosterone- induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells. Oncotarget 2017;8(50):87194-208.
10. Li F, Pascal LE, Zhou J, Zhou Y, Wang K, Parwani AV et al. BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib. Am J Clin Exp Urol 2018;6(1):1-10.
11. Wang K, Jin S, Fan D, Wang M, Xing N, Niu Y et al. Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene. PLoS One 2017;12(2):e0172233.
12. Kim SK, Chung JH, Lee BC, Lee SW, Lee HK, Kim YO et al. Influence of Panax ginseng on alpha-adrenergic receptor of benign prostatic hyperplasia. Int Neurourol J. 2014;18(4):179-86.
13. Nickel JC, Freedland SJ, Castro-Santamaria R, Moreira DM. Chronic prostate inflammation predicts symptom progression in patients with chronic prostatitis/chronic pelvic pain. J Urol. 2017;198(1):122-8.
14. Sebastianelli A, Gacci M. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus 2018;4(1):25-7.
15. Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC et al. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol 2014;66(4):752-68.
16. Ramreddy C, Rahul D, Vidyasagar S, Trivedi D, Arjun P. Analysis of risk factors and outcome of renal failure in benign prostatic hyperplasia. Journal of Clinical and Diagnostic Research 2018;12(1):1-3.